Zynerba's Pain Could Be GW Pharmaceuticals' Gain
For nearly all of 2017, Zynerba Pharmaceuticals (NASDAQ: ZYNE) handily outperformed GW Pharmaceuticals (NASDAQ: GWPH) stock. The operative word in that statement, though, is "nearly." Zynerba lost almost 70% of its market cap over the last three weeks.
On August 7, the biotech announced tremendously disappointing results from its phase 2 study of its cannabidiol (CBD) product, ZYN002, in treating adult epilepsy patients with focal seizures. Zynerba stock had already begun to slip in the days leading up to the clinical update, but it really tanked on the news about the study.
The pain for Zynerba could turn out to be a gain for GW Pharmaceuticals, though. Here's why.
Source: Fool.com
